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pts) for 6 months. Rest forced expiratory volume (FEV~), vital capacity (VC), 
total lung capacity (TLC), carbon monoxide diffusing capacity (DLco), its alve. 
olaf-capillary membrane component (DM), pulmonary venous and trensmitral 
flow velocitlel~ (for monitoring changes in LV and.diastolic pressure, EDP). left 
ventrlcular end.dlastolic (EDD) and end,systolic (ESD) dimensions, stroke 
volume (SV), ejection fraction (EF), fiber shodenlng velocity (Vcl) were mea- 
sured at baseline, 3 end 8 months, pVO=, peak dead epees to tidal volume 
ratio (pVDNT). ventllefory equivalent for CO;z production (VENCO=), VO~ at 
anaerobic threshold (VO~at) wore also determined, 
Result=: Compared with 14 healty voluntssr~. FEV~, VC, DLco, DM were 
Impalrod In CHF and did not Improve with carvadllol, It slgnlfleantty reduced 
LVEDP, BOB, BeD, and Increased SV, El=, Vcf but failed to ameliorate pVO~, 
VO~at. oVDNT. VENCO~ Placebo was not effective, Data at 3 and 6 months 
Cor~lu~/on~: Lack of pulmonary function Improvement desphe excellent 
amelioration at left ventrlculer function, suggs~lS the development in CHF of 
an Irreversible or slow reversible organio lung dleoase, or a need for phsrma. 
¢oioglcl~l pr0pedlss that carvedliol does not ponose, Persistent pulmoneP/ 
dysfunction may prevent pVO~ Improvement, 
• t ,ong,tefm Survive! lEft, at of in Dilated Metoprolo!  
Cardlomloplthy 
A, DI Len~rd~, R, DO M~rla, A, Gave=el, D, Gmgorl, M, ParotlnL G, S;insgra, 
L, ~lvstom, F, Long,m, E Bomoblch. F, CamortnL Oep~rtmenf at 
Caedtoto~, ~e;  Iat~f~ dt Fisiologl~ C/mica CNR, Mil~no, linty 
8~Ckl~0Un~: Although meloproiol (M) Is olfactlvo In dilated el~rdiomyop~thy 
(IDC), ~ontfolled ata am lacking on long term survival We evaluated the 
a~ect of M on long.term survival in 58~ pts with IDC. prospectively enrolled 
in a mufflcentsr registry and followed up for 52 t 32 months, M, uptttrated to 
the ma~lmum lolerated dose, was added to conventional therapy in 175 of 
them1 
R~ults: Soven,yo~r survtvel (8t% vs 60%, p .~ 0,0001) and transplant, 
free survival (69% w 49%, p ,= 0,0004) were higher In the 175 M.treatod 
pts 1hen in the 411 on standard treatment, By multivariate anatysls. M was 
as#colored to a 5t% redqetion for all.cause modallty (95% CI ~21 to 69%, 
p ,~ 0,00~) and a 34% for mortality or lransplentation (95% CI 5 to . 53%, p 
- 0,01), NYHA class, LV end diastolic diameter and palmonary wedge pros, 
sure w~l~ likewise predictive. Seven-year survival (80% v 62%, p ® 0,0036) 
and transplant-free suwlvat (68% v 51%, p = 0,0053) wore also higher in 
127 M,tmated cases than in 12"/controls, appropriately matched for key 
prognostic variables. Mpts showed a 30% reduction in all.cause mortality 
(98% CI to 48%, p = 0,0147) and a 26% reduction in mortality or 
transplantation (95% CI 7% to 41%, ~ = 0,0009), 
Conch~io~,~: The addition el metoprelol tO standard therapy, including 
ACE-tnhibltors, was effective in the long.term, reducing both all cause mor- 
tality and trnnsplant~tion mpatients with IDC, 
~ Beta,Blocker Therapy In Patients With Clinical 
Evidence o! Heart Failure After Acute Myocardial 
Infarction 
C,S, Spatulas, A,S, Hall, S,G, Ball. Institute for Cardiovascular Research, 
Unimrsity or Leeds, IlK 
B,'~ckground: Clinical evidence of congestive heart failure (HF) after acute 
myocardia! infarction (MI) is considered by many to be a contralndlcation to 
p-adrenergtc blockade, Furthermore, there is uncertainty as to the value of 
these agents following routine use of aspirin, thrembolytlc and ACE,inhibiter 
therapy, We examine clinical outcomes associated with optional to-blockade 
in a post MI population with evidence of HI=, 
Methods: We retrospectively analyzed data from the AIRE study (ran- 
domized, placebo-controlled trial of ramipril in 2006 post MI patients with 
clinical evidence of HF), At baseline, 20% o! the patients were receiving a 
t~-blocker, Diuretic treatment at randomization defined a high risk group with 
poorer left ventricular function (LVF). To eliminate confounding, we sepa- 
rately analyzed patients according to diuretic use, adjusting for the presence 
of multiple clinical signs of HF and 15 other baseline clinical variables. Each 
was simultaneously entered in a multivariate Cox regression model. 
Results: t~-blocker therapy was a significant independent predictor of 
reduction in the risk of all-cause mortality (34%. CI 10% to 51%, p .-:. 0,008) 
and severe HF t43%, C118 to 60%, p = 0.002) for the entire study population, 
Similar findings occurred in high risk patients receiving diuretic (39%, C110% 
to 58%, p = 0.012; 42%, CI 11% to 62%, p = 0.013) but not in those not 
requiring diuretic use (19%, CI -38 to 53%, NS; 41%, CI - 17% to 70%, NS). 
Conclusion: Our data indicate that in the modem era/~-blocker therapy 
benefits patients with clinical evidence of HF post MI. 
• Evidence Against Heart Rate Reduction aa the 
Primary Mechanism of  Act ion of  Carvedllol  In 
Chronic  Heart Failure 
J.D. Sockner.Bornateln, MIA, Lakes, B, Wu. For the U.S, Carvedilol 
InveBflgMOPa: Columbia Unlverel~ College of Physicians & Surgeorw New 
York, USA 
Carvedilol (CV) reduaee morbidity and modallty and Improvn quality of life 
In patients with head failure (HF). A mochanletio reid of hoed rata reduction 
(AHR) has been postulated, We evaluated the relationships betwoen the 
/~HR by CV and Its Iong.tam~ clinical and leR vQntdcular eff~"ts. 
Patients enrolled In the US tflats who received ¢awedllOI for their dou- 
ble.blind therapy were evaluated (n = 690), Moat had NYHA Iblll e/mpfoml, 
and mean ej~tion fraction (EF) was 0.23. CV was started at 6,25 mg BID 
and tltrated to 25.-50 mg BID over 4-,6 w~kll. ,~HR was ~l~lBted from 
the difference botween heed rates pdor Io and altQf titration, Logls~ m- 
gmseion was podormed to determine If ,.~HR wee re la~ to 1) progree,ldon 
el HF, 2) global assessment by physician and I~tlent, 3) ANYHA ¢!au, 4) 
Asympfom stalus, and 5) AEF PotioNs w~m divided by the n~dian ~HR 
with coml~aon ot outcome variable, 
~HR t'~ormlated signifimantly but weakly with ANYHA and ~I~F (r ~. 0,08, 
p ,= 0,03 and r ~ 0,15, p ~ 0,003, respe4:tively), Patients with the greatest 
AHR did not have a different clintoai out,=oma, 
,~HR door nat correlate strongly with the long.term effects of CV. Nauro, 
hormonal antagonism tndebendent of chronofm4~iQ effects m~y be the poman/ 
me(~hanism of benefit, The degree at ~,HR should not be the drama! 1elliot 
when treating patients with earvediiol, 
Eff~t of Carvedllol on Symptom 8¢om in Heart 
. . . .  Failure 
EM, Oilbml, M,A, Lukes, S, Wu, M,B, Fowler, For the US Carve~lol Hem1 
~ilure Study Group: Univen~ty of Utah. Salt Lake Cilg, UT, USA 
Patients (pts) in the US Carvedilol (C) Head Failure (HF) Tt~ls Program 
randdmi~ed to placebo (P, n ,= 398] or C (n = 698) had HF oymptoms 
assessed by a quantitative score of fatigue and of dyspnea (met, walking 
on level ground and climbing stairs) by a scale ot 0 (none) to 3 (severe). 
PIe' well,being was rated by a scale of 0 (YeW good) to 3 (Pcof)- Malimum 
possible overall score was 0-21, 
Results: Table o! within and between group (P vs C) changes at endpoint: 
Analyzed by baseline sevedty (submaxtmal exercise intoleraoceL overall 
Score improved on C vs P by 1,3 (p ~ 0.01), 0,5, and 1,8 (p = 0,10) in pts 
with mild, moderate or severe impairment, respectively. 
Question BL AP BL AC ,'~P vs C 
Ovoratl 8 4 063 8 3 1 27 0 64" 
Dyspnea-rest 0 5 0 04 0 5 0 04 O 08"" 
Dyspnea,level I I  O15 1.1 0 .17  00~ 
Dyspnea,stairs 1.? -0 18 1.7 -0.24 006 
Fatigue-i~st 00 ,0,07 08  ,0.11 0.04 
Fatigue.level 1.1 ~ 0 02 1.1 - O. 18 O, 16" 
Fatigue.eta(re 1 6 -.0.09 1,7 - 0.27 0.181 
Pts well,being 1 S Q.17 1.5 026 009 t 
• p = 0,Of:" p = 0,08: t p = 0003: t p = 0.09 [eL = t~sellno], 
Conclusion: Analyzed using a quantitative heart failure symptom score, 
canmdilol lreatment was associated with significant improvements in over, 
all score, and in exertional fatigue, with evidence for benefit regardless of 
baseline severity. 
• Contrast ing Effects o f  Intravenous Dofeti l ide and 
Amlodarene on Cardiac Sympathetic Ol ive in 
Patients With Congest ive Heart Failure 
M,F. Rousseau, P.E. Massart, L. Galanti, S.A. Ahn. J. Etienne, 
H,G. Pouleur. University of Louvain. Brussels. Belgium 
In contrast o IV dofetilide (DOF, a pure IKr blocker), IV amiodamne (AMIO) 
lowers aortic presstlre and hence, could trigger bamreceptor eflex. To assess 
the implications of this sy'~temic effect of AMIO at the cardiac level, corenaw 
sinus (CS) ~,ow (thermodilution) and aortic and CS norepinephrine (NE) 
concentrations were measured in 30 pts with congestive heart failure (NYHA 
II-IIh LVEF: 19 i 8%). before and after a 30 min infusion of placebo (P; n = 
12). DOF (8/4g/kg; n = 12) or AMIO (5 mg/kg; n = 6). CS flow was little affected 
by infusions (Pc +3.6°/o; DOF: -4.0%; AMIO: +4.7%; all NS) and myocardial 
02 consumption decreased slightly with all drugs (Pc -1.0 mllmin; AMIO: 
-0.2: DOF: -1.6: all NS). AMIO alone significantly decreased dP/dt Max 
and mean aortic P (-9 mmHg *&) whereas only DOF prolonged single lead 
QT (+106 ms *& vs + 10 with AMIO and +9 with P). However, AMIO increased 
